Coherus Oncology, Inc. (CHRS)

Nasdaq Biotechnology Diagnostics SIC: 2836
D
Pipeline Grade

Financial Position (from SEC Filings)

$115.5M
Cash & Equivalents
$57.9M
Quarterly Burn Rate
6 mo
Est. Cash Runway
$256M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (3)

NCT #TitlePhaseStatusEnrollment
NCT07423078 Window of Opportunity in Preserving Laryngeal Function Trial PHASE2 Recruiting 87
NCT07281716 Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC PHASE2 Recruiting 24
NCT06940180 Toripalimab With Chemotherapy for Sinus Cancer PHASE2 Recruiting 20

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for CHRS.

SEC EDGAR Filings

All SEC filings for Coherus Oncology, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.